Authors' reply to the comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32]

Affiliations

¹ Chongqing Medical Nutrition Research Center, Chongqing Key Laboratory of Nutrition and Food Safety, Research Center for Nutrition and Food Safety, Institute of Military Preventive Medicine, Third Military Medical University, Chongqing, China.
² Chongqing Medical Nutrition Research Center, Chongqing Key Laboratory of Nutrition and Food Safety, Research Center for Nutrition and Food Safety, Institute of Military Preventive Medicine, Third Military Medical University, Chongqing, China. Electronic address: mimantian@hotmail.com.

Comment

Jun-Dong Zhu et al. Dig Liver Dis. 2015 Dec.

. 2015 Dec;47(12):1090-1.

doi: 10.1016/j.dld.2015.08.012. Epub 2015 Aug 28.

¹ Chongqing Medical Nutrition Research Center, Chongqing Key Laboratory of Nutrition and Food Safety, Research Center for Nutrition and Food Safety, Institute of Military Preventive Medicine, Third Military Medical University, Chongqing, China.
² Chongqing Medical Nutrition Research Center, Chongqing Key Laboratory of Nutrition and Food Safety, Research Center for Nutrition and Food Safety, Institute of Military Preventive Medicine, Third Military Medical University, Chongqing, China. Electronic address: mimantian@hotmail.com.

No abstract available

Comment on

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q, Mi M. Chen S, et al. Dig Liver Dis. 2015 Mar;47(3):226-32. doi: 10.1016/j.dld.2014.11.015. Epub 2014 Dec 16. Dig Liver Dis. 2015. PMID: 25577300 Clinical Trial.
Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial.
Chen S, Zhao X, Wan J, Ran L, Qin Y, Wang X, Gao Y, Shu F, Zhang Y, Liu P, Zhang Q, Zhu J, Mi M. Chen S, et al. Pharmacol Res. 2015 Sep;99:74-81. doi: 10.1016/j.phrs.2015.05.009. Epub 2015 May 30. Pharmacol Res. 2015. PMID: 26032587 Clinical Trial.
Comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32].
Rotman Y. Rotman Y. Dig Liver Dis. 2015 Dec;47(12):1090. doi: 10.1016/j.dld.2015.08.011. Epub 2015 Aug 28. Dig Liver Dis. 2015. PMID: 26382727 No abstract available.